Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate

3/28/24 8:17:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AGRX alert in real time by email

Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.92) by 58.7 percent. This is a 83.78 percent increase over losses of $(9.00) per share from the same period last year. The company reported quarterly sales of $3.62 million which missed the analyst consensus estimate of $4.07 million by 11.18 percent. This is a 9.53 percent decrease over sales of $4.00 million the same period last year.

Get the next $AGRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AGRX

Date	Price Target	Rating	Analyst
11/3/2021	$3.50 → $2.50	Buy	HC Wainwright & Co.
9/13/2021	$7.00 → $3.50	Buy	HC Wainwright & Co.
7/27/2021	$6.00 → $5.00	Outperform	RBC Capital

More analyst ratings

$AGRX
Leadership Updates

Live Leadership Updates

Corium Pharma Solutions Names Suzanne Hinchliffe as Chief People Officer
Appointment of Experienced HR Executive Suzanne Hinchcliffe to Chief People Officer Continues Buildout of Experienced Leadership Team GRAND RAPIDS, Mich., March 1, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Suzanne Hincliffe as Chief People Officer. This announcement follows the recent appointments of several industry veterans to CPSI, Mark Sirgo as Chief Executive Officer, Ernie De Paloantonio as Chief Financial Officer, Kevin Ostrander as Chief Business Officer a
3/1/23 8:00:00 AM ET
$AGRX
$PG
Biotechnology: Pharmaceutical Preparations
Health Care
Package Goods/Cosmetics
Consumer Discretionary
Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer
Appointment of Ernie De Paolantonio to Chief Financial Officer Further Strengthens Leadership Team GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer. Appointment of Ernie De Paloantonio to
2/15/23 8:00:00 AM ET
$AGRX
$PG
Biotechnology: Pharmaceutical Preparations
Health Care
Package Goods/Cosmetics
Consumer Discretionary
Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer
Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,
1/17/23 8:00:00 AM ET
$AGRX
$GNTA
$NMTR
$PG
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Package Goods/Cosmetics

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
Agile Therapeutics has combined with Insud Pharma's US Subsidiary, Exeltis USA, Inc., expanding an already significant women's health/contraceptive portfolio Agile Therapeutics Common Shareholders to receive $1.52 per share of common stock Agile common stock will cease to be listed on the OTC QB PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. ("Agile") (OTCQB:AGRX), a women's healthcare company, today announced the completion of the acquisition of Agile by Insud Pharma, S.L. ("Insud") a global pharmaceutical group based in Spain with a 45-year track record and a presence in over 50 countries. The former holders of Agile common stock voted to approve the acq
8/26/24 5:05:00 PM ET
$AGRX
Biotechnology: Pharmaceutical Preparations
Health Care
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to receive $1.52 per share of common stock – approximately a 356% premium to the closing share price on June 25, 2024 Definitive Merger Agreement is subject to Agile Shareholder Approval. Agile Board is recommending shareholder approval of the Definitive Merger Agreement PRINCETON, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. ("Agile") (OTCQB:AGRX), a women's healthcare company, today announced that it has entered into a definitive merger agreement ("Merger Agreement") with
6/26/24 7:45:00 AM ET
$AGRX
Biotechnology: Pharmaceutical Preparations
Health Care
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. "We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sales in the first quarter from our fourth quarter 2023 results. We plan to continue to focus on executing our business plan, which we believe can continue to grow Twirla and enable us to manage our ope
5/15/24 4:10:00 PM ET
$AGRX
Biotechnology: Pharmaceutical Preparations
Health Care

Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. "We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sales in the first quarter from our fourth quarter 2023 results. We plan to continue to focus on executing our business plan, which we believe can continue to grow Twirla and enable us to manage our ope
5/15/24 4:10:00 PM ET
$AGRX
Biotechnology: Pharmaceutical Preparations
Health Care
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three and twelve months ended December 31, 2023 and provided a corporate update. "2023 was a year for Agile that we believe demon
3/28/24 8:05:00 AM ET
$AGRX
Biotechnology: Pharmaceutical Preparations
Health Care
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company's financial results and provide a business update. EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference CallDateThursday, March 28, 2024Time8:30 a.m. ET / 5:30 a.m. PT A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics
3/21/24 6:35:00 AM ET
$AGRX
Biotechnology: Pharmaceutical Preparations
Health Care

$AGRX
Market Insights

Live Market Insights

Agile Therapeutics Q1 2024 Adj EPS $(0.63) Misses $(0.51) Estimate, Sales $5.72M Beat $3.75M Estimate
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.51) by 23.53 percent. The company reported quarterly sales of $5.72 million which beat the analyst consensus estimate of $3.75 million by 52.35 percent. This is a 49.91 percent increase over sales of $3.81 million the same period last year.
5/15/24 4:43:30 PM ET
$AGRX
Biotechnology: Pharmaceutical Preparations
Health Care
Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.92) by 58.7 percent. This is a 83.78 percent increase over losses of $(9.00) per share from the same period last year. The company reported quarterly sales of $3.62 million which missed the analyst consensus estimate of $4.07 million by 11.18 percent. This is a 9.53 percent decrease over sales of $4.00 million the same period last year.
3/28/24 8:17:13 AM ET
$AGRX
Biotechnology: Pharmaceutical Preparations
Health Care
Agile Therapeutics: Q4 Earnings Insights
Agile Therapeutics (OTC:AGRX) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:05 AM. Here's what investors need to know about the announcement. Earnings Agile Therapeutics missed estimated earnings by -59.0%, reporting an EPS of $-1.46 versus an estimate of $-0.92. Revenue was down $381 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.37 which was followed by a 2.0% drop in the share price the next day. Here's a look at Agile Therapeutics's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -1.84 -3.48 -7.50 -11.5 EPS Actual -1.47 -3.10 -7.76 -9 Revenue Estimate 5.27M 4.68M 3.40M 3.
3/28/24 8:15:07 AM ET
$AGRX
Biotechnology: Pharmaceutical Preparations
Health Care

Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate

Chat with this insight

Recent Analyst Ratings for $AGRX

$AGRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Agile Therapeutics Inc.

SEC Form SC 13G filed by Agile Therapeutics Inc.

SEC Form SC 13G filed by Agile Therapeutics Inc.

$AGRX Leadership Updates

Live Leadership Updates

Corium Pharma Solutions Names Suzanne Hinchliffe as Chief People Officer

Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer

Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

$AGRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Administrative Officer Gilmore Geoffrey returned $30,789 worth of shares to the company (20,256 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Chief Financial Officer Coiante Scott M returned $30,522 worth of shares to the company (20,080 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Chief Supply Chain Officer Conway Robert G returned $20,564 worth of shares to the company (13,529 units at $1.52), closing all direct ownership in the company (SEC Form 4)

$AGRX SEC Filings

SEC Form RW filed by Agile Therapeutics Inc.

SEC Form EFFECT filed by Agile Therapeutics Inc.

SEC Form EFFECT filed by Agile Therapeutics Inc.

$AGRX Press Releases

Fastest customizable press release news feed in the world

$AGRX Financials

Live finance-specific insights

$AGRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.

Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.

Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update

Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024

HC Wainwright & Co. reiterated coverage on Agile Therapeutics with a new price target

HC Wainwright & Co. reiterated coverage on Agile Therapeutics with a new price target

RBC Capital reiterated coverage on Agile Therapeutics with a new price target

$AGRX Market Insights

Live Market Insights

Agile Therapeutics Q1 2024 Adj EPS $(0.63) Misses $(0.51) Estimate, Sales $5.72M Beat $3.75M Estimate